Regulatory data is for reference only. Always verify with the official regulator before making formulation decisions. Last refreshed: 10/12/2026.
Ingredients/Chrysene
ChryseneCAS 218-01-9
EU CosIng II — prohibitedASEAN II — prohibitedChina NMPA — prohibitedUK OPSS — prohibitedBrazil ANVISA — prohibited
Is Chrysene restricted in cosmetics?
Chrysene is prohibited in EU CosIng, ASEAN, China NMPA, UK OPSS and Brazil ANVISA. Markets not named here hold no entry for it, which is not a clearance.
- CAS
- 218-01-9
- INCI
- Chrysene
- Data refreshed
- 2026-10-12
Regulatory status
| Source | Status | Annex / Details | Limit / Conditions | Last updated |
|---|---|---|---|---|
| EU CosIng | prohibited | Annex II | — | — |
| ASEAN | prohibited | Annex II | — | — |
| China NMPA | prohibited | — | — | 10/7/2026 |
| UK OPSS | prohibited | — | Source: legislation.gov.uk retained EU Regulation 1223/2009 Annex Ii | 10/5/2026 |
| Brazil ANVISA | prohibited | — | — | 10/7/2026 |
What this means
Chrysene has regulatory signals in EU CosIng, ASEAN, China NMPA, UK OPSS, Brazil ANVISA. Review the source links above for the official conditions and latest updates.
Recent regulatory changes
No recorded regulatory changes for Chrysene yet.
Common questions
- Is Chrysene restricted in EU cosmetics?
- Chrysene is prohibited in EU cosmetics according to EU CosIng Annex II.
- Is Chrysene restricted under the ASEAN Cosmetic Directive?
- Chrysene is prohibited under the ASEAN Cosmetic Directive Annex II.
- Is Chrysene restricted in China NMPA?
- Chrysene is prohibited in cosmetics under China NMPA.
- Is Chrysene restricted in UK OPSS?
- Chrysene is prohibited in cosmetics under UK OPSS.
- Is Chrysene restricted in Brazil ANVISA?
- Chrysene is prohibited in cosmetics under Brazil ANVISA.
- What is the CAS number for Chrysene?
- The CAS number for Chrysene is 218-01-9.
Check this ingredient in a formula across 11 markets
This page covers one ingredient on its own. Sign up free to check it at your actual concentration, in a full formula, with GHS hazards and per-market verdicts.